Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

July 31, 2026

Conditions
PreDiabetes
Interventions
DRUG

Semaglutide

Glucagon-like Peptide 1 Receptor Agonist

Trial Locations (1)

78520

RECRUITING

UTHealth Clinical Research Unit (CRU) at UT Brownsville, Brownsville

All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER